Chondroitin Sulfate CS b-Bioactive Delays the Progression of Knee Osteoarthritis, Study Finds
28 Jun 2017 --- Bioiberica’s Chondroitin sulfate CS b-Bioactive delays osteoarthritis progression and is as effective as the anti-inflammatory drug celecoxib at improving the disease’s symptoms. These are the main conclusions of a clinical essay presented by Professor Jean Pierre Pelletier at the Annual European Congress of Rheumatology, held in Madrid. Conducted by Bioiberica, the MOSAIC clinical essay (a 24-month study on structural changes in knee osteoarthritis assessed by MRI with Chondroitin sulfate) is a multicenter, randomized, double-blind, controlled and comparative study, carried out in five medical centers in Quebec (Canada). A total of 194 patients suffering from knee osteoarthritis with inflammation (synovitis) and moderate pain participated in the study to assess the effects of chondroitin sulfate (1.200 mg/day) and celecoxib (200 mg day) over the loss of cartilage volume in knee osteoarthritis after 24 months. The participants underwent three Quantitative Magnetic Resonance scans: one at the beginning of the study, the second one after one year and a third one at the end of the study. The results revealed that the progression of knee osteoarthritis is slower in patients who received chondroitin sulfate CS b-Bioactive. This group experienced a statistically significant lower loss of cartilage volume as soon as after the first year of treatment, in comparison with those patients who received the anti-inflammatory drug. Patients treated with chondroitin sulfate had a decrease in synovitis which was associated with a statistically significant decrease in cartilage loss. In addition to that, a post hoc analysis of this clinical trial concludes that chondroitin sulfate also has a protective effect by reducing the long-term progression of knee OA structural changes caused by a decrease in the loss of subchondral bone curvature. “This data proves that chondroitin sulfate may delay the advance of osteoarthritis in the long term, and identifies a possible new mode of action of chondroitin sulfate,” Professor Pelletier said. The MOSAIC study also evaluated the effects of both products on the disease’s symptoms. Among others, the study evaluated their effects on pain, function, stiffness, joint swelling and effusion; concluding that both treatments were equally efficient across the entire study, reaching a clinically relevant symptom improvement of around 50 percent. “The study confirms that both products are effective for the treatment of osteoarthritis symptoms, although only chondroitin sulfate has the additional advantage of exerting a joint protection effect,” Professor Pelletier concludes. To contact our editorial team please email us at editorial@cnsmedia.com
Bioiberica S.A.U.
Collapse
COMPANY DETAILSBioiberica S.A.U. Pl. Francesc Macià, 7 08029 Barcelona Spain
http://www.bioiberica.com/inde ..
Tel. 0034 93 4904908 Fax. 0034 93 4909711 ACTIVE CATEGORIESMinerals and Food Supplements, Nutraceutical and Functional Food Ingredients Bioiberica is a biotechnology company specialized in the research, development, production and distribution of biomolecules such as Chondroitin Sulfate, Glucosamine and Hyaluronic Acid for the nutraceutical, pharmaceutical and food industries. Since 1975, Bioiberica has consolidated its position as an international leader in joint health, thanks to a constant dedication to science and technology. Vertically integrated, from the active ingredient to the finished product, Bioiberica places all its medical, scientific and marketing knowledge at the client’s disposal to achieve a leading and innovative line of joint care products. MOBILEE® the First Health Ingredient for Mobility Mobilee® has been researched and developed by Bioiberica, the Joint Health expert. Thanks to its native form, orally taken b-2Cool works through an immune-mediated mechanism of action called ORAL TOLERANCE, that modulates the immune response against endogenous type II collagen. It allows b-2Cool® to reduce cartilage degradation and joint inflammation, thus improving joint pain and function.
Tendofit® is a proprietary complex with a unique formula especially designed for tendon health and recovery. More that 6 scientific studies support its effectiveness. Clinical benefits of Tendofit® Tendon structure recovery Pain relief Anti-inflammatory effect Fast return activity
CS b-Bioactive® is #1 researched chondroitin. Its efficacy has been tested in +20 clinical studies and +5,000 patients. CS b-Bioactive® has demonstrated to be better absorbed and have higher biological effects compared to other chondroitins. It is manufactured to the highest pharmaceutical standards, being the reference standard of EP & USP.
Acti-Joint® composition: b-Glu (Bioiberica’s glucosamine) 1,500 mg CS b-Bioactive® (Bioiberica’s chondroitin sulfate) 200 mg Mobilee® (Natural ingredient rich in hyaluronic acid, polysaccharides and collagen) 20 mg
Palbio® is a cartilage complex containing chondroitin sulfate, hydrolyzed collagen and tricalcium phosphate, specially formulated to supply the main components of the joint in directly related nutritional values. The unique, carefully studied composition of Palbio nourishes the joint and improves its metabolism. Related ArticlesHealth & Nutrition News Student lunch picks: Milk and fruit losing out to fruit juice, study finds16 Nov 2018 --- High school students participating in school meal programs are less likely to select milk, whole fruit and water when fruit juice is available, which on balance may decrease the nutritional quality of their lunches, according to a new study by the Rudd Center for Food Policy and Obesity at the University of Connecticut. Health & Nutrition News Navigating the digestive health space: Probiotic strain specificity and microbiome key to future NPD16 Nov 2018 --- Emerging science linking a healthy microbiome to nearly every facet of health, as well as the ongoing media reporting on probiotics, have helped drive consumer interest in gut health. This growing area offers a wealth of opportunities to formulators, but due to regulatory demands and increasing consumer scrutiny, a clear view of how to navigate this space is vital. Health & Nutrition News Weekly Roundup: DSM enters Japanese partnership on healthy aging, Croda expands with Marine Biotechnology innovation center16 Nov 2018 --- In nutrition news this week, Croda opened a new Center of Innovation for Marine Biotechnology and DSM entered a collaboration on the development of services in nutritional rehabilitation and disease prevention in Japan. Lonza and Sartorius Stedim Biotech (SSB) are modifying their current agreement for the supply of cell culture media by mutual accord. Lastly, Gelita recently hosted a US symposium called, “The Sounds of Health and Nutrition,” which aimed to offer inspiration for market opportunities in the global health and nutrition marketplace. Health & Nutrition News Deep sea dinners? Future global food source may lie in cephalopods, study says15 Nov 2018 --- As the world’s population continues to expand and worries over strained global food resources grow, a recent article published in Frontiers is highlighting how cephalopods – squid, octopus and cuttlefish – could hold promise for our nutritional future. Under the initiative CephsInAction, the article calls for the use of the cephalopod population as a growing source of protein and a counterweight to the pressures facing global fisheries. Health & Nutrition News Cranberries found to reduce negative effects of animal-based diet on gut health15 Nov 2018 --- A Cranberry Institute and USDA-funded study into the potential protective effects of cranberries on the gut microbiome has found that adding cranberries to a meat-based diet can reduce the rise in secondary gut bile acids that have been associated with colon and GI cancer. The feeding trial – published in The Journal of Nutritional Biochemistry – found that the addition of whole cranberry powder to this common diet lessened potentially carcinogenic secondary bile acids and blunted the decline in beneficial short-chain fatty acids (SCFA) in the gastrointestinal (GI) tract. More Articles |
